Quick Summary:
Dive into the flourishing landscape of the global Hypercalcemia Treatment market with our intricately curated market research report. With the market estimated at a monumental US$18.7 Billion as of 2022, and projected to hit an outstanding figure of US$38.3 Billion by 2030, this report grants key insights for enterprises seeking to discern emerging trends, sector developments and competitive dynamics shaping this high-potential space.
Bisphosphonates, a critical segment spotlighted in this report, is set to witness a robust CAGR of 9.4%, reaching a substantial figure of US$25.2 Billion by 2030. This report also offers a macroscopic view of significant geographic markets including the US, China, Japan, Canada, and Germany. In this climate of rapid market evolution, our report equips businesses with vital data and in-depth analysis essential for strategic decision-making.
Beyond the numbers, we offer an incisive look at key players such as Abbvie, Inc., Merck & Co., Inc., and Novartis AG. This comprehensive, data-intensive report is accompanied with access to our digital archives, bespoke updates, and complimentary updates for one year, making it an essential tool for businesses aiming to successfully navigate the Hypercalcemia Treatment market.
Global Hypercalcemia Treatment Market to Reach $38.3 Billion by 2030
The global market for Hypercalcemia Treatment estimated at US$18.7 Billion in the year 2022, is projected to reach a revised size of US$38.3 Billion by 2030, growing at a CAGR of 9.4% over the analysis period 2022-2030. Bisphosphonates, one of the segments analyzed in the report, is projected to record 9.4% CAGR and reach US$25.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Calcitonin segment is readjusted to a revised 8.7% CAGR for the next 8-year period.
The U.S. Market is Estimated at $5.7 Billion, While China is Forecast to Grow at 8.6% CAGR
The Hypercalcemia Treatment market in the U.S. is estimated at US$5.7 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$6.5 Billion by the year 2030 trailing a CAGR of 8.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.7% and 7.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.6% CAGR.Select Competitors (Total 38 Featured) -
- AbbVie, Inc.
- Amgen, Inc.
- DiaSorin SpA
- Fujirebio Europe NV
- Kyowa Hakko Kirin Co., Ltd.
- Merck & Co., Inc.
- Novartis AG
- Opko Health, Inc.
- Rockwell Medical
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for Hypercalcemia Treatment?
What is the growth rate of the Global Market for Hypercalcemia Treatment?
What is the forecasted size of the Global Market for Hypercalcemia Treatment?
Who are the key companies in the Global Market for Hypercalcemia Treatment?
| Report Attribute | Details |
|---|---|
| No. of Pages | 192 |
| Published | December 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 18.7 Billion |
| Forecasted Market Value ( USD | $ 38.3 Billion |
| Compound Annual Growth Rate | 9.4% |
| Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- AbbVie, Inc.
- Amgen, Inc.
- DiaSorin SpA
- Fujirebio Europe NV
- Kyowa Hakko Kirin Co., Ltd.
- Merck & Co., Inc.
- Novartis AG
- Opko Health, Inc.
- Rockwell Medical
